Beta Bionics Inc.
BBNX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BBNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BBNX
Beta Bionics Inc. (BBNX) is a commercial-stage medical technology company focused on developing and commercializing the iLet bionic pancreas system for diabetes management, with a lead product generating $32.0M in revenue as of mid-2026.
Key risk: Continued operating losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Beta Bionics Inc..
Beta Bionics Inc. (BBNX) is a commercial-stage medical technology company focused on developing and commercializing the iLet bionic pancreas system for diabetes management, with a lead product generating $32.0M in revenue as of mid-2026.
- Cash & equivalents of $44.4M as of 2026-06-30 [sec].
- Total revenue of $32.0M for the six months ended 2026-06-30 [sec].
- Net loss of $23.4M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $301.6M as of 2026-06-30 [sec].
- Management expects existing cash and product sales to fund operations through the first half of 2028 [sec_mda · as of 2026-04-21].
What works
- Revenue generation from the iLet system provides a commercial revenue base, with $32.0M in revenue in the first half of 2026 [sec].
- Strong balance sheet with $301.6M in shareholders' equity and $44.4M in cash as of 2026-06-30, providing financial flexibility [sec].
- Management believes existing cash and product sales will fund operations through the first half of 2028, indicating a manageable cash runway [sec_mda · as of 2026-04-21].
What to weigh
- The company is not yet profitable, reporting a net loss of $23.4M in the first half of 2026 [sec].
- Significant ongoing R&D and commercialization expenses are expected to continue, with operating losses anticipated for the foreseeable future [sec_mda · as of 2026-04-21].
- Reliance on a single product (iLet) for revenue exposes the company to concentration risk [sec_mda · as of 2026-02-24].
From the filings
Quoted directly from source documents.
Cash runway through first half of 2028
“Based on our current operating plans, we believe that our existing cash, cash equivalents and short-term and long-term investments, as well as cash generated from sales of our products, will be sufficient to fund our projected operating expenses and capital expenditure requirements through the first half of 2028.”
SEC MD&A · April 21, 2026
Expectation of continued operating losses
“We expect to incur significant expenses and operating losses for the foreseeable future as we advance the commercialization of our iLet, including future development of the patch pump and bihormonal configuration of the iLet.”
SEC MD&A · May 6, 2025
Risks & what to watch (4)›
Key risks
- Continued operating losses — Net loss of $23.4M in H1 2026; expects significant expenses and losses for the foreseeable future [sec, sec_mda · as of 2025-05-06].
- Single product concentration — Revenue is entirely dependent on the iLet system; any disruption could materially impact financials [sec_mda · as of 2026-02-24].
- Clinical and regulatory uncertainty — Interim data may differ from final results; regulatory acceptance of data is uncertain [sec_mda · as of 2026-02-24].
- Macroeconomic and geopolitical risks — Tariffs, geopolitical tensions, and economic conditions could impact capital access and operations [sec_mda · as of 2026-04-21].
What to watch
- Progress in clinical development and regulatory submissions for the patch pump and bihormonal iLet configurations [sec_mda · as of 2025-05-06].
- Revenue growth trajectory and ability to achieve profitability as commercialization scales [sec].
- Cash burn rate and any need for additional capital beyond the projected runway through H1 2028 [sec_mda · as of 2026-04-21].
- Updates on the Clinical Supply Agreement with Xeris and associated development costs [sec_mda · as of 2026-04-21].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Beta Bionics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Beta Bionics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
38.8 months
D/E 0.14 · 0% dilution
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
0 buys · 15 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
127
Total value held
$394.9M
| Holder | Shares | Value |
|---|---|---|
| eventide asset management, llc | 5,945,488 | $59.6M |
| morgan stanley | 4,227,634 | $42.4M |
| farallon capital management llc | 3,607,920 | $36.2M |
| vanguard capital management llc | 3,455,954 | $34.6M |
| blackrock, inc. | 3,038,595 | $30.4M |
| rtw investments, lp | 2,000,000 | $20.0M |
| perceptive advisors llc | 1,685,888 | $16.9M |
| eversept partners, lp | 1,414,838 | $14.2M |
| deerfield management company, l.p. | 1,324,000 | $13.3M |
| omega fund management, llc | 1,316,183 | $13.2M |
Showing top 10 of 127 institutional holders of Beta Bionics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 14.0%
- Days to cover
- 5.1
- Shares short
- 6,194,778
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BBNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Beta Bionics Inc.?
Beta Bionics Inc. (BBNX) is a commercial-stage medical technology company focused on developing and commercializing the iLet bionic pancreas system for diabetes management, with a lead product generating $32.0M in revenue as of mid-2026.
What is Beta Bionics Inc.'s lead drug candidate?
Beta Bionics Inc.'s most advanced tracked candidate is mint (Preclinical) for Type 1 diabetes.
Who is the CEO of Beta Bionics Inc.?
Mr. Sean T. Saint PE is the chief executive officer of Beta Bionics Inc. (BBNX).
Where is Beta Bionics Inc. headquartered?
Beta Bionics Inc. (BBNX) is headquartered in Irvine, CA, United States.
What therapeutic areas does Beta Bionics Inc. focus on?
Beta Bionics Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.